广泛保护性单克隆抗体治疗埃博拉病毒病的研究进展

IF 5.7 2区医学 Q1 VIROLOGY

Current opinion in virology Pub Date : 2023-08-01 DOI:10.1016/j.coviro.2023.101339

Pramila Rijal , Francesca R. Donnellan

{"title":"广泛保护性单克隆抗体治疗埃博拉病毒病的研究进展","authors":"Pramila Rijal , Francesca R. Donnellan","doi":"10.1016/j.coviro.2023.101339","DOIUrl":null,"url":null,"abstract":"<div><p>The filovirus vaccine and the therapeutic monoclonal antibody (mAb) research have made substantial progress. However, existing vaccines and mAbs approved for use in humans are specific to <em>Zaire ebolavirus</em> (EBOV). Since other Ebolavirus species are a continuing threat to public health, the search for broadly protective mAbs has drawn attention. Here, we review viral glycoprotein-targeting mAbs that have proved their broader protective efficacy in animal models. MBP134<sup>AF</sup>, the most advanced of these new-generation mAb therapies, has recently been deployed in Uganda during the <em>Sudan ebolavirus</em> outbreak. Furthermore, we discuss the measures associated with enhancing antibody therapies and the risks associated with them, including the rise of escape mutations following the mAb treatment and naturally occurring EBOV variants.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"61 ","pages":"Article 101339"},"PeriodicalIF":5.7000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A review of broadly protective monoclonal antibodies to treat Ebola virus disease\",\"authors\":\"Pramila Rijal , Francesca R. Donnellan\",\"doi\":\"10.1016/j.coviro.2023.101339\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The filovirus vaccine and the therapeutic monoclonal antibody (mAb) research have made substantial progress. However, existing vaccines and mAbs approved for use in humans are specific to <em>Zaire ebolavirus</em> (EBOV). Since other Ebolavirus species are a continuing threat to public health, the search for broadly protective mAbs has drawn attention. Here, we review viral glycoprotein-targeting mAbs that have proved their broader protective efficacy in animal models. MBP134<sup>AF</sup>, the most advanced of these new-generation mAb therapies, has recently been deployed in Uganda during the <em>Sudan ebolavirus</em> outbreak. Furthermore, we discuss the measures associated with enhancing antibody therapies and the risks associated with them, including the rise of escape mutations following the mAb treatment and naturally occurring EBOV variants.</p></div>\",\"PeriodicalId\":11082,\"journal\":{\"name\":\"Current opinion in virology\",\"volume\":\"61 \",\"pages\":\"Article 101339\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1879625723000391\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879625723000391","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

丝状病毒疫苗和治疗性单克隆抗体（mAb）的研究取得了实质性进展。然而，批准用于人类的现有疫苗和单克隆抗体对扎伊尔埃博拉病毒（EBOV）具有特异性。由于其他埃博拉病毒物种对公众健康构成持续威胁，寻找具有广泛保护性的单克隆抗体引起了人们的关注。在此，我们综述了靶向mAb的病毒糖蛋白，这些mAb已在动物模型中证明了其更广泛的保护作用。MBP134AF是这些新一代单克隆抗体疗法中最先进的一种，最近在苏丹埃博拉病毒爆发期间部署在乌干达。此外，我们讨论了与增强抗体治疗相关的措施及其相关的风险，包括mAb治疗后逃逸突变的增加和自然发生的EBOV变异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A review of broadly protective monoclonal antibodies to treat Ebola virus disease

The filovirus vaccine and the therapeutic monoclonal antibody (mAb) research have made substantial progress. However, existing vaccines and mAbs approved for use in humans are specific to Zaire ebolavirus (EBOV). Since other Ebolavirus species are a continuing threat to public health, the search for broadly protective mAbs has drawn attention. Here, we review viral glycoprotein-targeting mAbs that have proved their broader protective efficacy in animal models. MBP134^AF, the most advanced of these new-generation mAb therapies, has recently been deployed in Uganda during the Sudan ebolavirus outbreak. Furthermore, we discuss the measures associated with enhancing antibody therapies and the risks associated with them, including the rise of escape mutations following the mAb treatment and naturally occurring EBOV variants.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current opinion in virology VIROLOGY-

CiteScore

11.80

自引率

5.10%

发文量

审稿时长

83 days

期刊介绍： Current Opinion in Virology (COVIRO) is a systematic review journal that aims to provide specialists with a unique and educational platform to keep up to date with the expanding volume of information published in the field of virology. It publishes 6 issues per year covering the following 11 sections, each of which is reviewed once a year: Emerging viruses: interspecies transmission; Viral immunology; Viral pathogenesis; Preventive and therapeutic vaccines; Antiviral strategies; Virus structure and expression; Animal models for viral diseases; Engineering for viral resistance; Viruses and cancer; Virus vector interactions. There is also a section that changes every year to reflect hot topics in the field.